Nectar Lifesciences Ltd.
NSE: NECLIFE | BSE: 532649
₹12.40
₹0.02
(0.16%)
As on 19-May-2026IST
Market cap
₹241 Cr
Revenue (TTM)
₹717 Cr
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-355 Cr
-
ROE
-11.2 %
-
ROCE
-5.2 %
-
Industry P/E
38.28
-
EV/EBITDA
-3.2
-
Debt to Equity
0.6
-
Book Value
₹36.2
-
EPS
₹-6.6
-
Face value
1
-
Shares outstanding
194,260,970
10 Years Aggregate
CFO
₹1,601.10 Cr
EBITDA
₹1,618.17 Cr
Net Profit
₹60.15 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nectar Lifescience
| -36.1 | -2.1 | -5.5 | -47.9 | -10.0 | -15.1 | -11.1 |
|
BSE Healthcare
| 9.5 | 9.4 | 9.8 | 12.1 | 27.6 | 14.5 | 11.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Nectar Lifescience
| -51.2 | 19.9 | 31.0 | -8.4 | 15.3 | 93.5 | -41.2 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nectar Lifescience
|
12.4 | 241.5 | 717.1 | -355.1 | -35.0 | -17.7 | -- | 0.3 |
| 1,061.6 | 13,022.0 | 2,551.8 | 564.5 | 28.3 | 18.4 | 23.1 | 3.9 | |
| 437.2 | 7,591.7 | 1,053.1 | 293.6 | 32.3 | 24.6 | 25.9 | 5.9 | |
| 1,143.5 | 11,962.9 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38.3 | 6.3 | |
| 1,710.2 | 32,465.3 | 9,203.5 | 941.3 | 15.4 | 19.6 | 35.1 | 6.6 | |
| 356.3 | 3,863.4 | 159.3 | 47.8 | 39.0 | 18.6 | 80.8 | 14.0 | |
| 16,790.0 | 21,520.2 | 2,023.0 | 364.0 | 23.9 | 20.8 | 59.1 | 11.5 | |
| 2,282.6 | 3,798.0 | 707.5 | 115.2 | 17.8 | 19.4 | 33 | -- | |
| 1,056.6 | 4,864.4 | 649.5 | 121.6 | 23.7 | 13.2 | 42.2 | 5.2 | |
| 269.4 | 7,094.1 | 7.1 | -276.3 | -4,077.5 | -63.3 | -- | 12.0 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Nectar Lifescience
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime... axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India. Read more
-
Incorporated
1995
-
Chairman
Sanjiv Goyal
-
Managing Director
Sanjiv Goyal
-
Headquarters
SAS Nagar Dist, Punjab
-
Website
Looking for more details about Nectar Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Nectar Lifescience
What is the current share price of Nectar Lifesciences Ltd Today?
The share price of Nectar Lifesciences Ltd is ₹12.40 (NSE) and ₹12.43 (BSE) as of 19-May-2026 IST. Nectar Lifesciences Ltd has given a return of -9.98% in the last 3 years.
What is the current PB & PE ratio of Nectar Lifesciences Ltd?
Since, TTM earnings of Nectar Lifesciences Ltd is negative, P/E ratio is not available.
The P/B ratio of Nectar Lifesciences Ltd is 0.34 times as on 19-May-2026, a 86 discount to its peers’ median range of 2.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.54
|
|
2024
|
135.18
|
0.63
|
|
2023
|
0.00
|
0.33
|
|
2022
|
21.53
|
0.50
|
|
2021
|
0.00
|
0.39
|
What is the 52 Week High and Low of Nectar Lifesciences Ltd?
The 52-week high and low of Nectar Lifesciences Ltd are Rs 28.25 and Rs 9.30 as of 20-May-2026.
What is the market cap of Nectar Lifesciences Ltd?
Nectar Lifesciences Ltd has a market capitalisation of ₹ 241 Cr as on 19-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Nectar Lifesciences Ltd?
Before investing in Nectar Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.